Eli Lilly and Company $LLY Position Increased by UniSuper Management Pty Ltd

Key Points

• UniSuper Management Pty Ltd has increased its holdings in Eli Lilly and Company by 11.7%, acquiring an additional 16,982 shares, bringing its total ownership to 161,664 shares valued at approximately $133.5 million.
• Multiple institutional investors, including PNC Financial Services and GAMMA Investing, significantly increased their stakes in Eli Lilly, highlighting a strong interest in the company among financial institutions.
• Eli Lilly recently announced quarterly earnings that surpassed analysts' expectations, reporting $6.31 earnings per share on revenue of $15.56 billion, marking a 37.6% increase year-over-year.

UniSuper Management Pty Ltd grew its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 161,664 shares of the company's stock after purchasing an additional 16,982 shares during the period. Eli Lilly and Company accounts for about 1.0% of UniSuper Management Pty Ltd's investment portfolio, making the stock its 17th largest position. UniSuper Management Pty Ltd's holdings in Eli Lilly and Company were worth $133,520,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of LLY. WestEnd Advisors LLC boosted its stake in shares of Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter worth approximately $27,000. Citizens National Bank Trust Department boosted its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after acquiring an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company in the first quarter worth approximately $40,000. Finally, Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth approximately $43,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 1.5%

Shares of LLY traded up $11.35 during mid-day trading on Tuesday, reaching $749.99. 2,983,536 shares of the stock traded hands, compared to its average volume of 4,135,773. The firm has a market cap of $709.83 billion, a price-to-earnings ratio of 49.02, a P/E/G ratio of 1.01 and a beta of 0.47. The stock has a fifty day simple moving average of $743.02 and a 200 day simple moving average of $779.63. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $942.35. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter last year, the firm posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 39.22%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 target price (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Erste Group Bank downgraded Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Leerink Partners reissued a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Finally, DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $950.17.

Insider Activity at Eli Lilly and Company

In related news, CEO David A. Ricks purchased 1,632 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the company's stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.